Peptidyl ketones as inhibitors of DPIV
The present invention relates to compounds of the general formula 1 and pharmaceutically acceptable salts thereof, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.
1. A compound formula 1:
or a pharmaceutically acceptable salts thereof, wherein:
A is selected from:
wherein
X 1 is H or an amino acid residue, a N-protected amino acid residue, a peptide residue or a N-protected peptide residue,
X 2 is H, —(CH) m —NH—C 5 H 3 N—Y with m=2-4, or —C 5 H 3 N—Y (a divalent pyridyl residue) and Y is selected from H, Br, Cl, I, NO 2 and CN,
X 3 is H or an alkyl-, alkoxy-, halogen-, nitro-, cyano- or carboxy-substituted phenyl or from an alkyl-, alkoxy-, halogen-, nitro-, cyano- or carboxy-substituted pyridyl residue,
X 4 is H or an alkyl-, alkoxy-, halogen-, nitro-, cyano- or carboxy-substituted phenyl or an alkyl-, alkoxy-, halogen-, nitro-, cyano- or carboxy-substituted pyridyl residue,
X 5 is H or an alkyl, alkoxy or phenyl residue,
X 6 is H or an alkyl residue,
for n=1
X is selected from OR 2 and SR 2 , wherein:
R 2 is an acyl residues, optionally substituted with alkyl, cycloalkyl, aryl or heteroaryl residues, or an amino acid residue or peptidic residue, or alkyl residue, which are optionally substituted with alkyl, cycloalkyl, aryl or heteroaryl residues,
for n=0
X is selected from:
wherein
B is O, S or NR 5 , wherein R 5 is H, alkyl or acyl,
C, D, E, F, G, Y, K, L, M, Q, T, U, V and W are independently selected from alkyl and substituted alkyl residues, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl residues, and
Z is H, or a branched or straight chain alkyl residue from C 1 -C 9 , a branched or straight chain alkenyl residue from C 2 -C 9 , a cycloalkyl residue from C 3 -C 8 , a cycloalkenyl residue from C 5 -C 7 , an aryl or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
2. A compound selected from the group consisting of
2-methylcarbonyl-1-N-[(L)-Alanyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromide;
2-methylcarbonyl-1-N-[(L)-Valinyl-(L)-Prolyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromide;
2-[(acetyloxy-methyl)carbonyl]-1-N-[(L)-Alanyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromide;
2-[(benzoyloxy-methyl)carbonyl]-1-N-[{(L)-Alanyl}-(L)-Valinyl]-(2S) -pyrrolidine hydrobromide;
2-{[(2,6-dichlorobenzyl)thiomethyl]carbonyl}-1-N-[{(L)-Alanyl}-(L)-Valinyl]-(2S)-pyrrolidine;
2-[(benzoyloxy-methyl)carbonyl]-1-N-[Glycyl-(L)-Valinyl]-(2S)-pyrrolidine hydrobromide;
2-[([1,3]-thiazol-2-yl)carbonyl]-1-N-[{(L)-Alanyl}-(L)-Valinyl]-(2S)-pyrrolidine trifluoracetate;
2-[(benzothiazol-2-yl)carbonyl]-1-N-[{(L-Alanyl}-(L)-Valinyl]-(2S)-pyrrolidine trifluoracetate;
2-[(-benzothiazol-2-yl)carbonyl]-1-N-[{(L)-Alanyl}-Glycyl]-(2S)-pyrrolidine trifluoracetate; and
2-[(pyridin-2-yl)carbonyl]-1-N[{(L)-Alanyl}-(L)-Valinyl]-(2S)-pyrrolidine trifluoracetate.
3. A pharmaceutical composition for parenteral, enteral or oral administration, characterised in that it contains at least one compound according to claim 1 optionally in combination with customary carriers or excipients.
4. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A is:
wherein
X 1 is H or an amino acid residue, an N-acylated amino acid residue, a peptide residue from di- to pentapeptides, or an N-protected peptide residue from di- to pentapaptides,
X 2 is H, —(CH) m —NH—C 5 H 3 N—Y with m=2-4, or —C 5 H 3 N—Y (a divalent pyridyl residue) and Y is selected from H, Br, Cl, I, NO 2 and CN,
for n=1
X is selected from OR 2 and SR 2 , wherein:
R 2 is an acyl residue, optionally substituted with alkyl, cycloalkyl, aryl or heteroaryl residues, or an amino acid residue or peptidic residue, or alkyl residue, optionally substituted with alkyl, cycloalkyl, aryl or heteroaryl residues,
for n=0
X is selected from:
wherein
B is O, S or NR 5 , wherein R 5 is H, alkyl or acyl,
C, D, E, F, G, Y, K, L, M and Q are independently selected from alkyl and substituted alkyl residues, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl residues; and
Z is H, or a branched or straight chain alkyl residue from C 1 -C 9 , a branched or straight chain alkenyl residue from C 2 -C 9 , a cycloalkyl residue from C 3 -C 8 , a cycloalkenyl residue from C 5 -C 7 , an aryl or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
5. A compound of formula 1:
or a pharmaceutically acceptable salt thereof, wherein A is:
wherein
n=0
X 1 is H or an amino acid residue, an N-acylated amino acid residue, or a dipeptide residue containing a Pro or Ala in the penultimate position, or an N-protected dipeptide residue containing a Pro or Ala in the penultimate position,
X is selected from:
wherein
B is O, C, D, E, F, G, Y, K, L, M and Q are H,
Z is H, or a branched or straight chain alkyl residue from C 3 -C 5 , a branched or straight chain alkenyl residue from C 2 -C 9 , a cycloalkyl residue from C 5 -C 7 , a cycloalkenyl residue from C 5 -C 7 , an aryl or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.